Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
If you rely on lower-cost compounded GLP-1 injections, plan now with your physician for a transition to an approved product, and be sure to avoid unapproved products or those marketed for research purposes. Will my insurance pay for name-brand GLP-1s
Semaglutide versus BPC-157 reconstitution If your first peptide experience was with BPC-157 , you are already familiar with the basic process
Belichenko PV, Wright EE, Belichenko NP, Masliah E, Li HH, Mobley WC, et al
However, just medication alone isnt going to create lasting change